The role of statins in managing diabetic dyslipidemia

Abstract

The common lipid abnormalities associated with T2DM confer substantial CV risk. Statins are a safe and well-established treatment option for lowering this atherogenic burden and improving outcomes in this patient population. Nonetheless, many patients with T2DM are not receiving a statin, and even those who receive treatment may not be achieving recommended lipid targets. Strategies must be implemented to improve the quality of care for these patients who are at high risk for a primary or secondary CV event.